# Lakefront Receives Transparency Notification from Madison Avenue Partners Canonical URL: https://biopharmsignal.com/news/GLPG/lakefront-receives-transparency-notification-from-madison-avenue-partners-747038a0 Ticker: GLPG Company: Galapagos NV Source: Galapagos NV Published: 2026-06-29 10:06 EST Original Source URL: https://www.glpg.com/press-releases/ ## Summary Mechelen, Belgium; June 29, 2026, 22.01 CET; regulated information – Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) received a transparency notification from Madison Avenue Partners.... ## Article Body Mechelen, Belgium; June 29, 2026, 22.01 CET; regulated information – Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) received a transparency notification from Madison Avenue Partners. Pursuant to Belgian transparency legislation 1 , Lakefront received a transparency notification from Madison Avenue Partners on June 24, 2026. The notification indicates that Madison Avenue Partners, LP, jointly with Madison Avenue International, LP, EMAI Management, LLC, and Eli Samaha, crossed above the threshold of 5% of Lakefront’ voting rights on an aggregated basis on June 15, 2026, following the acquisition of Lakefront’ voting rights. On June 24, 2026, Madison Avenue Partners (taking into account the holding of its affiliates) owned 3,498,892 voting rights, representing 5.31% of Lakefront’ currently outstanding 65,897,071 shares. Summary of the transaction: Date on which the threshold was crossed Date of notification Direct voting rights after the transaction Equivalent financial instruments after the transaction Total (%) voting rights June 15, 2026 June 24, 2026 3,498,892 0.00% 5.31% Content of the notification from Madison Avenue Partners: The notification dated June 24, 2026, contains the following information: • Date of notification: June 24, 2026 • Date on which the threshold is crossed: June 15, 2026 • Threshold of voting rights crossed (in %): 5% • Notification by: Madison Avenue Partners • Denominator: 65,897,071 • Reason for the notification: Acquisition or disposal of voting securities or voting rights • Notified details: A) Voting Rights Previous notification After the transaction # of voting rights # of voting rights % of voting rights Holder of voting rights Linked to securities Not linked to securities Linked to securities Not linked to securities Madison Avenue Partners, LP 0 3,498,892 5.31% B) Equivalent financial instruments After the transaction Holder of equivalent financial instruments Type of financial instrument Expiration date Exercise period or date # of voting rights that may be acquired if the instrument is exercised % of voting rights Settlement TOTAL 0 0.00% TOTAL (A&B) # of voting rights % of voting rights 3,498,892 5.31% The chain of control has been described at the end of the notification (section 11) and can be found here . About Lakefront ® Biotherapeutics Lakefront Biotherapeutics (formerly known as Galapagos) is a biotechnology company dedicated to building a differentiated pipeline of medicines for patients with serious diseases in areas of high unmet need. The Company has established a clinical‑stage portfolio in immunology and inflammation, anchored by gamgertamig, a potential first‑in‑class BCMAxCD3 T‑cell engager for autoimmune diseases. Backed by deep deal‑making expertise, operational flexibility, and a strong capital position, Lakefront identifies, acquires, and advances high‑quality assets with clear potential to deliver meaningful patient impact and long‑term shareholder value. For more information, visit https://www.lakefrontbio.com or follow us on LinkedIn or X . For further information, contact Lakefront Biotherapeutics: Investor Relations Sherri Spear +1 412 522 6418 sherri.spear@lakefrontbio.com 1 Belgian Act of 2 May 2007 on the disclosure of major shareholdings in issuers whose shares are admitted to trading on a regulated market and regarding miscellaneous provisions, as amended from time to time. TN Madison June 2026_EN ## Recent Company News - 2026-07-13 12:00 EST — [Lakefront Announces Paulo Fontoura has Resigned from its Board following his Appointment as Global Head of R&D at Sanofi](https://biopharmsignal.com/news/GLPG/lakefront-announces-paulo-fontoura-has-resigned-from-its-board-following-his-app-f92a2665) — Source: Galapagos NV - 2026-07-07 10:07 EST — [Acquisition of Own Shares](https://biopharmsignal.com/news/GLPG/acquisition-of-own-shares-7c1425be) — Source: Galapagos NV - 2026-06-30 10:06 EST — [Acquisition of Own Shares](https://biopharmsignal.com/news/GLPG/acquisition-of-own-shares-7c02dc9d) — Source: Galapagos NV - 2026-06-29 10:06 EST — [Lakefront Receives Transparency Notification from Madison Avenue Partners](https://biopharmsignal.com/news/GLPG/lakefront-receives-transparency-notification-from-madison-avenue-partners-747038a0) — Source: Galapagos NV - 2026-06-09 12:00 EST — [Acquisition of Own Shares](https://biopharmsignal.com/news/GLPG/acquisition-of-own-shares-9c121987) — Source: Galapagos NV ## Related News - 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47) - 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0) - 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f) - 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c) - 2026-07-20 13:00 EST — ENLV — [Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion](https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-nav-per-ordinary-share-66-16-total-treasury-ho-9d036ef9)